Videos

E. David Crawford, MD: Safety and Tolerability Issues

June 18th 2015

E. David Crawford, MD: Options to Control Recurrent Metastatic Disease

June 18th 2015

Judd W. Moul, MD, FACS: Chemotherapy Consideration

June 18th 2015

Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease

June 18th 2015

Metastatic Prostate Cancer: Case 1

June 18th 2015

Metastatic Prostate Cancer

Pierre Gholam, MD: Treatment Selection

June 18th 2015

Pierre Gholam, MD: Alcohol Abuse Impact on Treatment

June 18th 2015

Nicholas Nissen, MD: Treatment Selection

June 18th 2015

Nicholas Nissen, MD: Monitoring of Patient

June 18th 2015

Richard Finn, MD: Treatment Selection

June 18th 2015

Richard Finn, MD: Most Appropriate Treatment

June 18th 2015

Unresectable Hepatocellular Carcinoma: case 3

June 18th 2015

Unresectable Hepatocellular Carcinoma

Pierre Gholam, MD: Potential for Systemic Therapy

June 18th 2015

Pierre Gholam, MD: Recommended Screening

June 18th 2015

Nicholas Nissen, MD: Potential for Systemic Therapy

June 18th 2015

Nicholas Nissen, MD: Estimate of TACE Procedures

June 18th 2015

Richard Finn, MD: Potential for Systemic Therapy

June 18th 2015

Richard Finn, MD: Significance of Baseline AFP Levels

June 18th 2015

Unresectable Hepatocellular Carcinoma: case 2

June 18th 2015

Unresectable Hepatocellular Carcinoma

Pierre Gholam, MD: Consideration of Different Modalities

June 18th 2015

Pierre Gholam, MD: Next Steps for Jose

June 18th 2015

Nicholas Nissen, MD: Next Steps for Jose

June 18th 2015

Nicholas Nissen, MD: Consideration of Different Modalities

June 18th 2015

Richard Finn, MD: Next Steps for Jose

June 18th 2015

Richard Finn, MD: Consideration of Different Modalities

June 18th 2015

Unresectable Hepatocellular Carcinoma: case 1

June 18th 2015

Unresectable Hepatocellular Carcinoma

Denise A Yardley MD: Controlling Metastatic Disease

June 18th 2015

Denise A. Yardley, MD: Taxane Resistance

June 18th 2015

Denise A. Yardley, MD: Triple-Negative Phenotype's Influence on Treatment

June 18th 2015

William J. Gradishar, MD: Triple-Negative Phenotype's Influence on Treatment

June 18th 2015

Videos

E. David Crawford, MD: Safety and Tolerability Issues

E. David Crawford, MD: Options to Control Recurrent Metastatic Disease

Judd W. Moul, MD, FACS: Chemotherapy Consideration

Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease

Metastatic Prostate Cancer: Case 1

Pierre Gholam, MD: Treatment Selection

Pierre Gholam, MD: Alcohol Abuse Impact on Treatment

Nicholas Nissen, MD: Treatment Selection

Nicholas Nissen, MD: Monitoring of Patient

Richard Finn, MD: Treatment Selection

Richard Finn, MD: Most Appropriate Treatment

Unresectable Hepatocellular Carcinoma: case 3

Pierre Gholam, MD: Potential for Systemic Therapy

Pierre Gholam, MD: Recommended Screening

Nicholas Nissen, MD: Potential for Systemic Therapy

Nicholas Nissen, MD: Estimate of TACE Procedures

Richard Finn, MD: Potential for Systemic Therapy

Richard Finn, MD: Significance of Baseline AFP Levels

Unresectable Hepatocellular Carcinoma: case 2

Pierre Gholam, MD: Consideration of Different Modalities

Pierre Gholam, MD: Next Steps for Jose

Nicholas Nissen, MD: Next Steps for Jose

Nicholas Nissen, MD: Consideration of Different Modalities

Richard Finn, MD: Next Steps for Jose

Richard Finn, MD: Consideration of Different Modalities

Unresectable Hepatocellular Carcinoma: case 1

Denise A Yardley MD: Controlling Metastatic Disease

Denise A. Yardley, MD: Taxane Resistance

Denise A. Yardley, MD: Triple-Negative Phenotype's Influence on Treatment

William J. Gradishar, MD: Triple-Negative Phenotype's Influence on Treatment

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

ASCO 2026 Highlights: Breast & Lung Cancer Advances With Ajaz Khan, MD

Sunvozertinib Outperforms Chemotherapy as First-Line Therapy for EGFR Exon 20–Mutant NSCLC

ASCO Roundup: Rare Melanomas and Skin Cancers

FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma

FDA Grants RMAT Designation to Lasme-Cel for Relapsed/Refractory B-ALL